Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.

摘要: T cells genetically modified to stably express immunoreceptors are being assessed for therapeutic potential in clinical trials. expressing a chimeric antigen receptor (CAR) endowed with new specificity target tumor-associated (TAA) independent of major histocompatibility complex. Our approach nonviral gene transfer uses ex vivo numeric expansion CAR on irradiated artificial presenting (aAPC) bearing the targeted TAA. The requirement aAPC desired TAA limits human application CARs multiple specificities when selective through coculture feeder is sought. As an alternative individual TAAs aAPC, we expressed 1 ligand that could activate sustained proliferation specificity. We (designated CARL) binds conserved IgG4 extracellular domain and demonstrated CARL propagate specificities. avoids technical issues costs associated deploying clinical-grade each by given CAR. Using enables numerically expand all containing domain, simplifies expansion, testing, translation any